Women’s health is a perspective of prevention and treatment that looks at health concerns unique to females. Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. Recently there have been major changes in government and private support of women’s health research -- in policies, regulations, and the organization of research efforts. In a recent Institute of Medicine (IOM) report, the Washington DC-based institute found that women’s health research has contributed to significant progress over the past 20 years in lessening the burden of disease and reducing deaths from some conditions for women, while other conditions have seen only moderate change or even little or no change. Gaps remain, both in research areas and in the application of results to benefit women in general and across multiple population groups.Viewing women’s health exclusively as a function of sex differences is too narrow, according to the IOM report. It frames women’s health and well-being as a function only of biological factors and how they differ in men and women, and ignores the role of gender, which is affected by broader social and community factors. The IOM finds that there has been inadequate attention paid to the social and environmental factors that, along with biologic risk factors, influence women’s health. Although progress has been made in identifying behavioral determinants of women’s health, such as smoking, diet, and physical activity, few studies have tested ways to modify these determinants in women or examined the effects of social and community factors in specific groups of women. To advance this area of research, the IOM recommends that the National Institutes of Health (NIH) support research on common determinants and risk factors that underlie multiple diseases.
Significant progress has been made in reducing mortality for women from breast cancer, cardiovascular disease and cervical cancer. This can be attributed in part to increased consumer demand and awareness, which has resulted in additional funding and research; improved diagnosis; screening and treatment; and, in the case of cervical cancer, a vaccine.
Viewing women’s health exclusively as a function of sex differences is too narrow, according to the IOM report. It frames women’s health and well-being as a function only of biological factors and how they differ in men and women, and ignores the role of gender, which is affected by broader social and community factors. The IOM finds that there has been inadequate attention paid to the social and environmental factors that, along with biologic risk factors, influence women’s health. Although progress has been made in identifying behavioral determinants of women’s health, such as smoking, diet, and physical activity, few studies have tested ways to modify these determinants in women or examined the effects of social and community factors in specific groups of women. To advance this area of research, the IOM recommends that the National Institutes of Health (NIH) support research on common determinants and risk factors that underlie multiple diseases.
Significant progress has been made in reducing mortality for women from breast cancer, cardiovascular disease and cervical cancer. This can be attributed in part to increased consumer demand and awareness, which has resulted in additional funding and research; improved diagnosis; screening and treatment; and, in the case of cervical cancer, a vaccine.
All reports in Women's Health
|
Emergency Contraception in Latvia
5/8/2012 | published by: Euromonitor International
... was decreasing in Latvia, which explained growth of emergency contraception. Euromonitor International's Emergency Contraception in Latvia report offers a comprehensive guide to the size and shape of the market at a national level. It provides ...
|
more...
|
$900.00
|
|
Triple Analysis: Breast Cancer, Lymphoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Cancer Vaccines and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Colorectal Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
... criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also ...
|
more...
|
$5,175.00
|
|
European Market for Nutritional Solutions in Women's Health
3/28/2012 | published by: Frost & Sullivan
... Market engineering measurements, including historical and forecasted revenues and growth rates, have been provided for the study period - 2007 to 2017. In addition, drivers and restraints for the market, application analysis, competitive structure, and ...
|
more...
|
$6,000.00
|
|
Female Sexual Dysfunction – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... the therapeutic development for Female Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction. 'Female Sexual ...
|
more...
|
$500.00
|
|
Human Papillomavirus Infections – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... the therapeutic development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections. 'Human Papillomavirus ...
|
more...
|
$500.00
|
|
Menopausal Hot Flashes – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... the therapeutic development for Menopausal Hot Flashes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Hot Flashes. 'Menopausal Hot ...
|
more...
|
$500.00
|
|
Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... provides information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine ...
|
more...
|
$500.00
|
|
Menopausal Disorders – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Menopausal Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Disorders. 'Menopausal Disorders - Pipeline Review, H1 2012' ...
|
more...
|
$500.00
|
|
Cervical Dysplasia – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Cervical Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Dysplasia. 'Cervical Dysplasia - Pipeline Review, H1 2012' ...
|
more...
|
$500.00
|
|
Vaginal Atrophy – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Vaginal Atrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Atrophy. 'Vaginal Atrophy - Pipeline Review, H1 2012' ...
|
more...
|
$500.00
|
|
Emergency Contraception in Lithuania
3/14/2012 | published by: Euromonitor International
... emergency contraception products following the switch in 2009, the global credit crunch and the collapse of the overheated economy prevented the area from achieving its potential. In 2011, spending on product promotion fell as priorities ...
|
more...
|
$900.00
|
|
Endometriosis
3/1/2012 | published by: Global Industry Analysts
... period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 32 companies including many key and niche players such as Abbott Laboratories, AEterna Zentaris, Inc., AstraZeneca Plc, Bayer ...
|
more...
|
$4,600.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Angiogenesis
3/1/2012 | published by: BioSeeker Group AB
... a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Lung Cancer and Pancreatic Cancer
3/1/2012 | published by: BioSeeker Group AB
... assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas. Below is a short ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
3/1/2012 | published by: BioSeeker Group AB
... criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines
3/1/2012 | published by: BioSeeker Group AB
... in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between ...
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Prostate Cancer
3/1/2012 | published by: BioSeeker Group AB
... assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas. Below is a short ...
|
more...
|
$5,175.00
|
|
Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2/29/2012 | published by: GlobalData
... The report is an essential source of information and analysis on the global Postmenopausal Vaginal Atrophy Therapeutics market. The report identifies the key trends shaping and driving the global Postmenopausal Vaginal Atrophy Therapeutics market. The ...
|
more...
|
$3,995.00
|


